Amphastar Pharmaceuticals to Present at the 2017 Wells Fargo Securities Healthcare Conference
August 30 2017 - 6:00AM
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that
Jason Shandell, President will be presenting at the 2017 Wells
Fargo Securities Healthcare Conference on Wednesday, September 6,
2017 at 1:50 p.m. Eastern Time in Boston, MA.
This presentation will be made available with a
live webcast and may be accessed by visiting Amphastar’s
Pharmaceuticals website at http://ir.amphastar.com/events.cfm .
This webcast will be available for 90 days following the
presentation.
About Amphastar:
Amphastar is a specialty pharmaceutical company that focuses
primarily on developing, manufacturing, marketing, and selling
technically-challenging generic and proprietary injectable,
inhalation, and intranasal products. Additionally, the Company
sells insulin active pharmaceutical ingredient products. Most of
the Company’s finished products are used in hospital or urgent care
clinical settings and are primarily contracted and distributed
through group purchasing organizations and drug wholesalers. More
information is available at the Company’s website at
www.amphastar.com.
The Amphastar Pharmaceuticals’ logo and other trademarks or
service marks of Amphastar Pharmaceuticals, Inc., including,
but not limited to Primatene®, Amphadase® and Cortrosyn®, are the
property of Amphastar Pharmaceuticals, Inc.
Forward-Looking Statement:
All statements in this press release and in the conference call
referenced above that are not historical are forward-looking
statements, including, among other things, statements relating to
the Company’s expectations regarding future financial performance,
backlog, sales and marketing of its products, market size and
growth, the timing of FDA filings or approvals, acquisitions and
other matters related to its pipeline of product candidates, the
timing for completion of construction at the Company’s IMS
facility, its share buyback program and other future events. These
statements are not historical facts but rather are based on
Amphastar’s historical performance and its current expectations,
estimates, and projections regarding Amphastar’s business,
operations and other similar or related factors. Words such as
“may,” “might,” “will,” “could,” “would,” “should,” “anticipate,”
“predict,” “potential,” “continue,” “expect,” “intend,” “plan,”
“project,” “believe,” “estimate,” and other similar or related
expressions are used to identify these forward-looking statements,
although not all forward-looking statements contain these words.
You should not place undue reliance on forward-looking statements
because they involve known and unknown risks, uncertainties, and
assumptions that are difficult or impossible to predict and, in
some cases, beyond Amphastar’s control. Actual results may differ
materially from those in the forward-looking statements as a result
of a number of factors, including those described in Amphastar’s
filings with the Securities and Exchange Commission. You can locate
these reports through the Company’s website at
http://ir.amphastar.com and on the SEC’s website at www.sec.gov.
Amphastar undertakes no obligation to revise or update information
in this press release or the conference call referenced above to
reflect events or circumstances in the future, even if new
information becomes available or if subsequent events cause the
Company’s expectations to change.
Contact:
William J. Peters
Chief Financial Officer
(909) 476-3416
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Sep 2023 to Sep 2024